At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
Sarcosine Capsule +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease
In Brief
A clinical study evaluating Sarcosine Capsule and Placebo Capsule for Parkinson's Disease With Dementia. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The project will investigate the effect of pharmacological and electric modulation of N-methyl-D-aspartate (NMDA) pathway on the cognitive flexibility and volitional movement preparation in patients with Parkinson's disease (PD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease With Dementia
CountriesTaiwan
CollaboratorsNational Science and Technology Council, Taiwan
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
Primary CompletionJun 2012
Study CompletionJul 2012
First PostedFeb 2013
TodayJul 2026
First PostedFeb 7, 2013
Enrollment StartAug 1, 2010
Primary CompletionJun 1, 2012
Study CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.4 years ago
Interventions
Sarcosine Capsuledietary
Sarcosine is a glycine transporter-1 (GlyT-1) inhibitor. By blocking glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor function.
Placebo Capsuledietary
Placebo is dextrin composition.